Brookline downgraded CervoMed (CRVO) to Hold from Buy and suspended the firm’s price target on the shares following the failure of the company’s Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO: